High Dose Aflibercept Formulation for Extended Injection Intervals
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neovascular age-related macular degeneration (nAMD) require frequent intravitreal injections of VEGF antagonists, posing a significant burden on patients and healthcare systems due to the need for regular administration, which can lead to non-compliance and increased treatment-related burdens.
Innovation Solution
Administering higher doses of aflibercept (≥8 mg) with an aqueous pharmaceutical formulation containing a VEGF receptor fusion protein, formulated with L-arginine, sucrose, and a histidine-based buffer, to slow clearance from the ocular compartment and extend the time to reach the lower limit of quantitation, allowing for longer treatment intervals such as every 12 to 20 weeks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent intravitreal injections are administered to maintain therapeutic efficacy, then visual outcomes are maintained or improved, but treatment burden on patients and healthcare systems increases
Solution Approach 1:
The patent changes the concentration parameter of aflibercept from standard doses (2mg, 4mg) to high dose (8mg), which fundamentally alters the pharmacokinetic profile and extends the duration of therapeutic effect, thereby reducing injection frequency from every 4-8 weeks to potentially every 12 weeks or longer
Solution Approach 2:
The patent employs a dynamic dosing strategy where the initial high dose (8mg) creates a prolonged therapeutic window, allowing the treatment interval to be extended over time. This dynamic approach adapts the dosing schedule based on the extended half-life and sustained efficacy profile of the high dose formulation
2Productivity
If higher dose aflibercept (≥8 mg) is administered to extend treatment intervals, then injection frequency is reduced and treatment burden decreases, but drug clearance rate and duration of action must be optimized
Solution Approach 1:
The patent systematically optimizes multiple formulation parameters including concentration (≥8mg/0.07mL), pH (5.0-6.8), and excipient composition to achieve the desired pharmacokinetic profile. These parameter changes collectively extend the duration of action by slowing clearance while maintaining therapeutic efficacy
Solution Approach 2:
The patent uses a composite aqueous formulation containing aflibercept combined with specific excipients (histidine buffer, arginine, sucrose, polysorbate) that work synergistically to stabilize the drug, reduce clearance, and extend duration of action in the ocular compartment
3Ease of manufacture
If standard concentration formulations are used, then manufacturing and administration are straightforward, but treatment intervals remain short requiring frequent injections
Solution Approach 1:
The patent increases the drug concentration parameter to ≥8mg in a small volume (0.07mL), achieving high dose delivery without proportionally increasing formulation complexity. This parameter change extends the therapeutic window and reduces injection frequency while maintaining manufacturing feasibility
Solution Approach 2:
The patent transitions from thinking in terms of injection frequency (time dimension) to thinking in terms of total annual injections (cumulative burden dimension). The high dose formulation reduces the cumulative number of injections required per year, addressing the treatment burden from a different dimensional perspective
Data Source
AI summary
The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, characterized by high doses of aflibercept and extended intervals between doses.